Minocycline in Neurocognitive Outcomes - Sickle Cell Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 15, 2026

Conditions
Sickle Cell DiseaseCognitive ImpairmentCognitive DeclineCognitive ChangeCognitive DysfunctionCognitive DeficitNeuroinflammatory Response
Interventions
DRUG

Minocycline

Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.

DRUG

Placebo

This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.

All Listed Sponsors
lead

University of Cincinnati

OTHER